TacticScaleWhat Krystal Biotech Does & How It Makes Money (KRYS)
Updated October 2026 · reflects Krystal Biotech's latest reported financials
Commercial-stage biotech developing and selling gene therapies for rare diseases. The company earns revenue by selling its approved gene therapy VYJUVEK in the United States, which it manufactures itself.
How Krystal Biotech makes money
The company earns revenue by selling its approved gene therapy VYJUVEK in the United States, which it manufactures itself. It spends on developing a pipeline of additional genetic medicines that could become future products.
What Krystal Biotech does
Krystal Biotech is a commercial-stage biotechnology company based in Pittsburgh, founded in 2016. It discovers, develops, manufactures and sells genetic medicines for diseases with high unmet medical need. Its first commercial product, VYJUVEK (beremagene geperpavec), treats dystrophic epidermolysis bullosa (DEB), a rare inherited skin-blistering disorder, and provides the company's product revenue in the US. The pipeline extends the platform into other areas. In ophthalmology, KB803 targets eye complications of DEB and KB801 targets neurotrophic keratitis. In respiratory disease, KB407 (cystic fibrosis) and KB408 (Alpha-1 antitrypsin deficiency) are in Phase 1 trials. KB707 is in Phase 1/2 trials for solid tumors, including anti-PD-1 relapsed/refractory cases. In dermatology and aesthetics, KB111 targets Hailey-Hailey disease, KB304 targets dynamic wrinkles and KB301 is in Phase 2 for aesthetic skin conditions.
Products & services
- VYJUVEK (B-VEC)
- KB803 (ophthalmic B-VEC)
- KB407
- KB408
- KB707
- KB301
What is Krystal Biotech worth?
On an owner-earnings DCF, Krystal Biotech's most-likely value is about $334 versus a recent price near $332 (1% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$82) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Vericel (VCEL) · Vertex Pharmaceuticals (VRTX) · Cytokinetics (CYTK) · Sarepta Therapeutics (SRPT) · Vir Biotechnology (VIR)